Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Shen-Cun Fang1,2
Hai-Tao Zhang1
Ying-Ming Zhang1
Wei-Ping Xie2

1Department of Respiratory Medicine Center, Nanjing Chest Hospital, 2Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China

Abstract: In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this setting is poor. Apatinib, a small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, is a first-generation oral antiangiogenesis drug approved in the People’s Republic of China for use as a subsequent line of treatment for advanced gastric cancer. Herein, we report three cases of advanced NSCLC with epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative status, wherein the patients showed partial response to apatinib. Moreover, the three patients have achieved a progression-free survival of 2.8, 5.8, and 6 months, respectively. The main toxicities were hypertension, proteinuria, and hand–foot syndrome. Apatinib may provide an additional option for the treatment of advanced NSCLC, especially for advanced lung adenocarcinoma without a driver mutation.

Keywords: non-small-cell lung cancer, angiogenesis, apatinib, VEGFR-2

Introduction

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide.1 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors are currently recommended as the best treatment option for patients harboring EGFR mutations and ALK rearrangements, respectively.2,3 Checkpoint blockade blockers have also demonstrated promising responses in NSCLC patients with PD-L1 expression.4 For the majority of NSCLC patients without a genetic driver mutation, platinum-based doublet chemotherapy is the standard treatment option for advanced NSCLC.5,6 However, most patients experience disease progression within 6 months from first-line therapy and require salvage therapy.7 Docetaxel and pemetrexed are considered standard second-line therapies based on several randomized controlled trials.8,9 Despite the fact that a considerable proportion of patients (26%–38%) are suitable for post second-line therapies,10 the quality and quantity of the available drugs in this setting is poor.

Apatinib, a small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) TKI, is a first-generation oral antiangiogenesis drug approved in the People’s Republic of China for use as a subsequent line of treatment for advanced gastric cancer. However, there is no report focusing on its efficacy and safety in patients with NSCLC. Herein, we report three cases of advanced NSCLC with EGFR wild-type and ALK-negative status, wherein the patients showed partial response (PR) to apatinib.
Case presentation

Patient I, a 70-year-old nonsmoking female, was admitted with a 1-month history of cough and chest pain. A chest computed tomography (CT) scan revealed a large mass in the right lower lobe with a small amount of right pleural effusion and pericardial effusion. Brain magnetic resonance imaging indicated the presence of multiple intracranial metastatic tumors. No metastasis was observed on abdominal ultrasound examination and whole body bone scan. CT-guided percutaneous right pulmonary biopsy indicated lung adenocarcinoma. No gene mutations were detected in EGFR or ALK examination. The diagnosis was right lung adenocarcinoma with multiple intracranial metastases (Table 1). Doublet chemotherapy of cisplatin and pemetrexed was administered for two cycles; the therapeutic evaluation was progressive disease (PD). Docetaxel was prescribed as second-line chemotherapy. Re-evaluation imaging after 2 months demonstrated an increase in the size of pulmonary metastases, with multiple metastases in the left lung and left malignant pleural effusion. The patient experienced severe dyspnea and had a performance status (PS) of 4. Then, she received apatinib treatment (500 mg/day) and PR was detected after 2 weeks of treatment (Figure 1).

In addition, dyspnea diminished within 4 days and the PS of the patient improved from 4 to 2. Progression-free survival (PFS) after apatinib treatment was 2.8 months. The main toxicities were proteinuria and hypertension (Table 1).

Patient II, a 42-year-old female who is a never-smoker, was admitted with a 2-month history of cough. Chest CT showed that there was a lesion at the right upper lobe, with multiple metastases in the right lung and right pleural effusion. Adenocarcinoma cells were found in the pleural effusion. Cellular immunohistochemistry studies confirmed primary adenocarcinoma of the lung. The patient was diagnosed with stage IV non-small-cell lung adenocarcinoma. The pleural effusion specimen from this patient was tested for EGFR and ALK. The findings showed that EGFR mutations and ALK were negative (Table 1). The patient was administered six cycles of pemetrexed/cisplatin from August 2014; the therapeutic evaluation was PR. The patient was further given six cycles of pemetrexed maintenance therapy from February 2015. As second-line therapy, carboplatin and docetaxel were prescribed for four cycles from September 2015; the therapeutic evaluation was stable disease (SD). Chemotherapy of “gemcitabine and nedaplatin” was administered for one cycle from January 2016 as a third-line treatment. Re-evaluation chest CT demonstrated an increase in the size of pulmonary metastases. The patient developed a poor general condition. She received apatinib treatment (500 mg/day) from March 2016 and showed PR after 1 month (Figure 2). She has achieved a PFS of 5.8 months. The toxicities the patient experienced were mainly hand–foot skin reaction and hypertension, which were well managed (Table 1).

Patient III, a 66-year-old man who is a light smoker, was admitted with a 1-month history of cough. Chest CT showed a right upper lobe mass of about 2 cm, with multiple metastases in the lower lobe of right lung and right pleural effusion. Adenocarcinoma cells were found in the pleural effusion. Cellular immunohistochemistry confirmed primary adenocarcinoma of the lung. Gene detection showed that the ALK rearrangement was negative and EGFR was wild-type (Table 1). As first-line chemotherapy, the regimen of “pemetrexed plus cisplatin” was initiated for four cycles from May 2015. The therapeutic evaluation was SD. Repeat evaluation imaging (December 2015) demonstrated that the right pulmonary lesions increased rapidly. Chemotherapy consisting of “docetaxel plus carboplatin” was prescribed as a second-line treatment. Following two cycles of chemotherapy, the patient developed worsening dyspnea and had a PS of 3. Re-evaluation showed disease progression in the right lung lesions. Therefore, treatment with apatinib (500 mg/day)

Table 1 Baseline characteristics of patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70</td>
<td>42</td>
<td>66</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Smoking</td>
<td>No</td>
<td>No</td>
<td>Light smoker</td>
</tr>
<tr>
<td>Pathologic type</td>
<td>Adenocarcinoma</td>
<td>Adenocarcinoma</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Gene type</td>
<td>EGFR</td>
<td>ALK</td>
<td>Stage</td>
</tr>
<tr>
<td></td>
<td>Wild-type</td>
<td>Negative</td>
<td>IV (cT4N2M1b)</td>
</tr>
<tr>
<td></td>
<td>Wild-type</td>
<td>Negative</td>
<td>IV (cT4N1M1a)</td>
</tr>
<tr>
<td></td>
<td>Wild-type</td>
<td>Negative</td>
<td>IV (cT4N1M1a)</td>
</tr>
<tr>
<td>Therapy (response)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First line</td>
<td>Pemetrexed/ cisplatin (PR)</td>
<td>Pemetrexed/ cisplatin (PR)</td>
<td>Pemetrexed/ cisplatin (SD)</td>
</tr>
<tr>
<td>Second line</td>
<td>Docetaxel (PD)</td>
<td>Docetaxel/ carboplatin (SD)</td>
<td>Docetaxel/ carboplatin (PD)</td>
</tr>
<tr>
<td>Third line</td>
<td>Apatinib (PR)</td>
<td>Gemcitabine/ nedaplatin (PD)</td>
<td>Apatinib (PR)</td>
</tr>
<tr>
<td>Fourth line</td>
<td></td>
<td>Apatinib (PR)</td>
<td></td>
</tr>
<tr>
<td>CEA (µg/mL)</td>
<td>Pre-apatinib 85</td>
<td>28</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Post-apatinib 35</td>
<td>16</td>
<td>20</td>
</tr>
<tr>
<td>PFS (months)</td>
<td>2.8</td>
<td>5.8</td>
<td>6</td>
</tr>
<tr>
<td>Adverse events</td>
<td>Hypertension Grade 2</td>
<td>Grade 3</td>
<td>Grade 3</td>
</tr>
<tr>
<td></td>
<td>Hand–foot syndrome Grade 2</td>
<td>Grade 2</td>
<td>Grade 2</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>Grade 1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ALK, anaplastic lymphoma kinase; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
Figure 1 Patient I: Computed tomography shows the mass in the right lung with left lung metastasis and pleural effusion (A) before apatinib treatment and (B) after apatinib treatment was given for 2 weeks.

Figure 2 Patient II: Computed tomography shows the mass in the right lung (A) before apatinib treatment and (B) after apatinib treatment was given for 1 month.
was administrated as a third-line treatment. After 3 weeks of treatment with apatinib, PR was detected in the right lung lesion (Figure 3) and PS of the case improved from 3 to 1. The patient’s PFS has increased to 6 months after taking apatinib. The only toxicity was grade 3 hypertension, which was well relieved by antihypertensive treatment without dose adjustment (Table 1).

Discussion
Tumor angiogenesis plays a critical role in tumor growth, development, and metastasis. Serum VEGF activates VEGFR-2, inducing a cascade of different signaling pathways, promoting endothelial cell migration and proliferation necessary for angiogenesis. Given its central role in cancer angiogenic process, several agents targeting VEGF/VEGFR-2 axis have been developed for inhibition of tumor angiogenesis and have shown encouraging efficacy in several tumor types.

However, blockage of VEGF pathway in advanced NSCLC by either adding antiangiogenic agents to chemotherapy or administering VEGFR TKIs as a single agent has caused more failures than successes. We now have two antiangiogenic agents targeting VEGF/VEGFR-2 axis have been developed for inhibition of tumor angiogenesis and have shown encouraging efficacy in several tumor types.

Figure 3 Patient III: Computed tomography shows the mass in the right lung (A) before apatinib treatment and (B) after apatinib treatment was given for 3 weeks.

Apatinib is a novel small-molecule oral agent that strongly and selectively inhibits VEGFR-2 activation. Biologic and preclinical evidence suggests that apatinib effectively blocks proliferation and tube formation of human umbilical vein endothelial cells, and inhibits the growth of xenograft tumors. Interestingly, it also can circumvent cancer cell resistance to chemotherapeutic drugs by directly inhibiting ABCB1 and ABCG2 function. A multicenter Phase II study demonstrated that apatinib is active in metastatic breast cancer patients and shows encouraging rates of disease stabilization and PFS. A Phase III study shows that apatinib, administered as monotherapy, significantly prolonged OS and PFS in patients with advanced gastric cancer experiencing progression after two or more lines of chemotherapy. An in vitro study revealed apatinib could inhibit the proliferation and metastasis
of lung cancer cells. This successful drug is currently being investigated in patients with lung cancer.

Because of the intolerant toxicities of chemotherapy or unsatisfactory therapeutic effect, apatinib was administered after two or more lines of chemotherapy in the three cases mentioned above. Apatinib (850 mg/day) was recommended for the treatment of metastatic gastric cancer in a Phase III study, but dose modifications resulting from its toxicity were very common. In patients with metastatic breast cancer who received apatinib 750 mg/day in a Phase IIa trial, serious adverse events and drug-related deaths occurred. Therefore, a lower dose of apatinib (500 mg/day) was subsequently administered in the Phase IIb study. Considering the safety issues, the cases mentioned above were treated with apatinib 500 mg/day. The most frequently reported side effects of apatinib were hypertension, proteinuria, and hand–foot syndrome. In our cases, grade 2–3 hypertension and hand–foot skin reaction occurred with a dose of 500 mg/day and they were well managed.

Although the three patients mentioned above who were treated with apatinib achieved PR, patient I’s PFS only increased to 2.8 months, which is far less than that in the other two patients. In the ECOG 4599 study, elderly patients did not benefit from treatment with bevacizumab. Similar to this study, the subgroup of patients of age ≥70 years derived no benefit from therapy with ramucirumab in the REVEL trial. These results implied that elderly patients could obtain little benefit from antiangiogenic treatments.

Though apatinib did show its effective therapeutic action in NSCLC, especially in advanced lung adenocarcinoma without a driver mutation, it is unclear as to how to select patients who are more likely to be responsive to apatinib. It is hoped that further biomarker analyses will help to screen for appropriate patients with NSCLC.

**Acknowledgments**

The authors thank the patients for their participation in the study and agreeing to publish the report.

Written informed consent was obtained from the three patients for publication of this case series and the accompanying images. This case series was approved by the medical ethics committee of the Nanjing Chest Hospital.

**Author contributions**

All authors contributed toward data analysis, drafting, and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**
